BiotechTube

ORENCIA Subcutaneous Injection

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

Jun 7, 2016 → Nov 15, 2023

NCT ID
NCT02758769

About ORENCIA Subcutaneous Injection

ORENCIA Subcutaneous Injection is a pre-clinical stage product being developed by Ono Pharmaceutical for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02758769. Target conditions include Rheumatoid Arthritis.

What happened to similar drugs?

20 of 20 similar drugs in Rheumatoid Arthritis were approved

Approved (20) Terminated (0) Active (0)
✅Baricitinib + TNF InhibitorEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved
✅TacrolimusAstellas PharmaApproved
✅TacrolimusAstellas PharmaApproved
✅Methotrexate (MTX)EisaiApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02758769Pre-clinicalCompleted

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®Dr. Reddy's LaboratoriesPhase 3
37
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
TilmanoceptNavidea BiopharmaceuticalsPhase 1
11
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
LY2127399Eli LillyPhase 3
32
Baricitinib + TNF InhibitorEli LillyApproved
43
CT-P17 SC AI (adalimumab)CelltrionPhase 3
40
Remsima IV + Remsima SCCelltrionPre-clinical
33
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P47 + EU-approved RoActemraCelltrionPhase 3
40
InfliximabCelltrionPhase 3
40
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
Rituximab, MTX, folic acidCelltrionPhase 1
29
CT-P10 + Rituxan + MabTheraCelltrionPhase 3
40
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)CelltrionPhase 3
36
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 3
40